|
Oct 4
|
Aura Biosciences, Inc. (NASDAQ:AURA) is a favorite amongst institutional investors who own 58%
|
|
May 30
|
Aura Biosciences to Participate in the Jefferies Global Healthcare Conference
|
|
May 10
|
Aura Biosciences Inc (AURA) Reports Q1 2024 Earnings: A Detailed Financial Overview
|
|
May 9
|
Aura Biosciences Reports First Quarter 2024 Financial Results and Business Highlights
|
|
May 8
|
One Aura Biosciences Insider Raised Stake By 232% In Previous Year
|
|
Mar 28
|
We're Not Very Worried About Aura Biosciences' (NASDAQ:AURA) Cash Burn Rate
|
|
Mar 27
|
Aura Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
|
|
Mar 17
|
11 Oversold Biotech Stocks To Buy Right Now
|
|
Dec 7
|
Aura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial Evaluating the Safety and Efficacy of Belzupacap Sarotalocan (Bel-sar) for First-Line Treatment of Early-Stage Choroidal Melanoma
|
|
Nov 8
|
Aura Biosciences to Participate in Upcoming Investor Conferences
|
|
Nov 7
|
Aura Biosciences Announces Pricing of Public Offering of Common Stock
|
|
Nov 6
|
Aura Biosciences Announces Proposed Public Offering of Common Stock
|
|
Nov 6
|
Aura Biosciences Receives FDA Agreement Under Special Protocol Assessment (SPA) for CoMpass Phase 3 Clinical Trial of Belzupacap Sarotalocan (Bel-sar) in Early-stage Choroidal Melanoma
|
|
Aug 9
|
Aura Biosciences Reports Second Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights
|